Atomoxetine
- Generic Name
- Atomoxetine
- Brand Names
- Strattera
- Drug Type
- Small Molecule
- Chemical Formula
- C17H21NO
- CAS Number
- 83015-26-3
- Unique Ingredient Identifier
- ASW034S0B8
- Background
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associat...
- Indication
Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Associated Therapies
- -
Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility
- Conditions
- Interventions
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 18
- Registration Number
- NCT00953862
Driving in Adults With Attention-deficit/Hyperactivity Disorder (ADHD) Before and During Treatment With Atomoxetine
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2011-01-20
- Lead Sponsor
- Central Institute of Mental Health, Mannheim
- Target Recruit Count
- 50
- Registration Number
- NCT00938743
- Locations
- 🇩🇪
Central Institute of Mental Health, Adult ADHD Outpatient Department, Mannheim, Germany
Impact of Strattera and Behavior Therapy on the Home and School Functioning of Children With ADHD
- Conditions
- Interventions
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- State University of New York at Buffalo
- Target Recruit Count
- 56
- Registration Number
- NCT00918567
- Locations
- 🇺🇸
Cennter for Children and Families, Buffalo, New York, United States
Atomoxetine, Placebo and Parent Management Training in Autism
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 128
- Registration Number
- NCT00844753
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine
- First Posted Date
- 2008-10-27
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 56
- Registration Number
- NCT00780650
- Locations
- 🇺🇸
Univerisity of Maryland, Baltimore, Baltimore, Maryland, United States
Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder(ADHD)
- First Posted Date
- 2008-09-26
- Last Posted Date
- 2011-09-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 112
- Registration Number
- NCT00760747
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Northampton, United Kingdom
Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia
- Conditions
- Interventions
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 110
- Registration Number
- NCT00716274
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
Efficacy Study of Strattera for Treating Attention Disorders in Traumatic Brain Injury (TBI)
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Craig Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00702364
- Locations
- 🇺🇸
Craig Hospital, Englewood, Colorado, United States
Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE
- Conditions
- Interventions
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2010-08-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 7
- Registration Number
- NCT00687609
- Locations
- 🇳🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Den Haag, Netherlands
Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2010-11-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 45
- Registration Number
- NCT00636818
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.